● Recruiting

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Condition: Metabolic Syndrome · Obesity & Overweight · HIV (Human Immunodeficiency Virus) · Sponsor: Abdelrahman Mahmoud

PhasePhase 2

Planned participants66

Who can joinAll sexes, 18 Years to 65 Years

Healthy volunteersNo

About this study

We investigate the role of empagliflozin in the treatment of obesity in PLWH.

This description comes directly from the study's public registry record.

Talk to the study team

Abdelrahman Dosoky, Bachelor's degree · +201148534951 · abdelrahman.ibrahim@pharma.cu.edu.eg

Ahmed Kamel, PhD · +20 100 676 6275 · ahmedm.kamel@pharma.cu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Faculty of Pharmacy, Cairo University | Kasr El-Aini, Cairo

Cairo, Egypt

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07336797